# US ADME Toxicology Testing Market

> US ADME Toxicology Testing Market Research Report By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), By Technology (Cell Culture, High Throughput, Molecular Imaging, OMICS Technology), By Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, Others) and By End-Users (Hospitals and clinics, Diagnostic centers, Pathological Labs, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.63%
- **2024:** $ 1,276.42 Million
- **2025:** $ 1,373.81 Million
- **2035:** $ 2,866 Million
- **Key Players:** Thermo Fisher Scientific (US), Agilent Technologies (US), PerkinElmer (US), Charles River Laboratories (US), Sierra Sciences (US), Eurofins Scientific (LU), Covance (US), Bioanalytical Systems (US), Wuxi AppTec (CN)

**Report ID:** MRFR/LS/17738-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-adme-toxicology-testing-market-19285

---

## Market Summary

## **US ADME Toxicology Testing Market Overview**

### **Market Size and Growth**

As per MRFR analysis, the US ADME Toxicology Testing Market Size was estimated at 148.74 (USD Million) in 2023. The US ADME Toxicology Testing Market Industry is expected to grow from 166.74(USD Million) in 2024 to 893.39 (USD Million) by 2035. The US ADME Toxicology Testing Market CAGR (growth rate) is expected to be around 16.486% during the forecast period (2025 - 2035).

### **Key US ADME Toxicology Testing Market Trends Highlighted**

The US ADME Toxicology Testing Market is experiencing significant growth driven by several key market drivers. An increasing emphasis on drug safety and the need for regulatory compliance play major roles in shaping this market. The US Food and Drug Administration (FDA) and other regulatory bodies are setting stringent guidelines that require comprehensive toxicology testing as part of the drug development process. This regulatory landscape is compelling pharmaceutical companies to invest more in toxicology testing services to align with safety standards, thus driving market demand.

Opportunities abound for innovation in this sector, especially with the advancement of in vitro technologies and computational toxicology, which can provide more accurate and reliable results while saving time and costs in drug development. Furthermore, the ongoing shift towards personalized medicine opens new avenues for ADME toxicology testing services that cater specifically to individualized patient responses to medications. Trends in recent times have also highlighted the adoption of high-throughput screening technologies, which allow for faster testing and better risk assessment in early drug development stages.

Additionally, there is a growing interest in using biomarkers for toxicity testing, improving the relevance and predictive power of toxicological assessments. These developments are indicative of an industry that is rapidly evolving, with more focus on reducing the reliance on animal testing and utilizing alternative methods that align with ethical considerations. Overall, the US market reflects a blend of regulatory compliance demands, evolving technologies, and a strong commitment to improving drug safety, making it a dynamic landscape for ADME toxicology testing.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US ADME Toxicology Testing Market Drivers**

### **Rising Drug Development Activities**

The US ADME Toxicology Testing Market Industry is experiencing significant growth due to the increasing number of drug development activities. The Food and Drug Administration (FDA) reported that over 1,000 new drugs were approved in the US in the past five years, a clear indicator of a robust pharmaceutical landscape. This surge necessitates thorough toxicological assessments to evaluate the safety and efficacy of new compounds. Furthermore, industry giants such as Pfizer and Merck are ramping up their Research and Development (R&D) efforts, investing billions in the discovery of new therapies.

As a result, the demand for Advanced Drug Metabolism and Excretion (ADME) toxicology testing is set to rise, aligning with the industry's need for faster, reliable evaluations in preclinical phases.

### **Increasing Incidence of Chronic Diseases**

With chronic diseases on the rise, the demand for robust toxicology testing is intensifying in the US. According to the Centers for Disease Control and Prevention (CDC), six in ten Americans are living with at least one chronic condition such as heart disease or diabetes, leading to an urgent need for innovative treatments. This situation creates a favorable environment for the US ADME Toxicology Testing Market Industry, as pharmaceutical companies are compelled to ensure that their new therapies are safe for a growing patient demographic.

The focus on understanding drug metabolism and possible toxicity is crucial in advancing new treatments, which is driving market growth.

### **Regulatory Requirements for Drug Approval**

Stringent regulatory requirements laid out by agencies such as the FDA are another driver for the US ADME Toxicology Testing Market Industry's growth. The FDA has implemented rigorous guidelines that require comprehensive toxicological data before any drug can be approved. This mandates increased reliance on ADME toxicology testing to ensure compliance and is fostering a growing market for these services. Companies such as GSK and Johnson & Johnson are increasingly investing in toxicology testing to fulfill these regulations, ensuring their products are not only effective but also safe for consumers, thus boosting the overall market demand.

## **US ADME Toxicology Testing Market Segment Insights**

### **ADME Toxicology Testing Market Method Insights**

The Method segment of the US ADME Toxicology Testing Market encompasses various innovative approaches essential for evaluating the absorption, distribution, metabolism, and excretion of substances, playing a crucial role in drug development and safety assessment. Among these methods, Cellular Assay techniques are significantly prevalent as they provide valuable information on cell viability, cytotoxicity, and the biochemical interactions of compounds at the cellular level. This method allows for a robust understanding of how drugs interact with living cells, thereby assisting in the early detection of toxic effects.

Biochemical Assays contribute substantially by measuring the biochemical activity of compounds and their effects on biological systems, offering crucial insights needed for risk assessment and regulatory compliance. In Silica approaches have gained prominence as they utilize computer-based simulations to predict the behavior of compounds, significantly reducing the time and resources required for experimental testing while enhancing the predictive accuracy of toxicological data. Meanwhile, Ex-vivo testing involves studying the effects of substances on biological samples extracted from living organisms, providing a realistic view of how these substances would behave in a living system.

Each of these methodologies presents unique advantages and is essential for a comprehensive understanding of toxicological profiles, contributing to more informed decision-making in Research and Development settings. With the growing emphasis on efficient drug testing and regulatory requirements in the US, these methodologies are becoming increasingly vital, reflecting the evolving nature of the US ADME Toxicology Testing Market. Notably, the integration of these methods with advanced technologies also creates opportunities for improved accuracy and reduced animal testing, which is becoming an important consideration in both regulatory frameworks and ethical practices within the industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **ADME Toxicology Testing Market Technology Insights**

The Technology segment of the US ADME Toxicology Testing Market encompasses several key areas that are crucial for drug development and safety assessment. Cell Culture technologies are integral as they provide a controlled environment for studying cell behavior and the efficacy of compounds. High Throughput technologies dominate the landscape due to their ability to process large volumes of samples quickly and efficiently, significantly speeding up the screening process in pharmaceutical research. Molecular Imaging plays a vital role by enabling real-time visualization of biological processes, thus enhancing understanding of drug action and toxic effects.

[Spatial OMICS](../../../reports/spatial-omics-market-21572) Technology, which includes genomics, proteomics, and metabolomics, is important for its comprehensive approach to analyzing biological molecules, offering insights into the complex pathways affected by drug substances. These advancements are driving innovations in the industry, addressing the need for more effective testing methodologies to ensure safety and efficacy in drug development, which is particularly relevant given the regulatory pressures and the growing demand for personalized medicine in the US market.

### **ADME Toxicology Testing Market Application Insights**

The US ADME Toxicology Testing Market, particularly in the Application segment, is experiencing notable evolution as it encompasses critical areas such as Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and others. Systemic Toxicity testing plays a fundamental role in drug development, ensuring that compounds are safe when taking into account the overall physiological effects on the body. Renal Toxicity is garnering increased attention due to the high prevalence of kidney-related issues in patients, highlighting the need for detailed evaluations of drug impacts on renal function.

Hepatotoxicity assessments are paramount, as liver damage from pharmaceutical agents is a common concern in medication toxicity, necessitating thorough testing. Likewise, Neurotoxicity evaluations are crucial given the significant number of drugs affecting the nervous system, which can lead to long-term health implications if not adequately assessed. Collectively, these areas reflect a comprehensive approach to toxicity testing in the US, emphasizing patient safety and optimizing the drug development pipeline. Understanding the intricacies of these applications aids in improving drug design while aligning with regulatory requirements, enhancing the overall US ADME Toxicology Testing Market industry.

### **ADME Toxicology Testing Market End-Users Insights**

The US ADME Toxicology Testing Market accounted for a significant share, highlighting the essential role played by End-Users in ensuring drug safety and efficacy. Hospitals and clinics are crucial in this segment, as they often require comprehensive toxicology testing to support their patient care processes and clinical trials. Diagnostic centers also contribute considerably, providing specialized testing services that help identify potential drug interactions and toxic effects. Pathological Labs are vital for conducting detailed analyses that inform both treatment decisions and regulatory submissions.

Additionally, the 'Others' category includes various research institutions and pharmaceutical companies that utilize toxicology testing to support their Research and Development initiatives. This segmentation reflects the growing adoption of advanced testing methodologies within the US healthcare system, driven by stricter regulatory requirements and an increasing focus on personalized medicine. Collaboration between these end-users promotes innovation and efficiency in toxicology testing, enhancing drug development processes and patient outcomes. Overall, the segment continues to evolve in response to the expanding demand for stringent testing protocols that ensure drug safety and efficacy in real-world applications.

## **US ADME Toxicology Testing Market Key Players and Competitive Insights**

The US ADME Toxicology Testing Market is characterized by a dynamic and highly competitive landscape where numerous players vie for market share. This market has witnessed significant growth, driven by the increasing demand for drug discovery and development processes, coupled with stringent regulatory requirements necessitating thorough safety assessments of pharmaceutical compounds. The competitive insights reveal that companies are focusing on innovation, technological advancements, and strategic collaborations to enhance their service offerings and improve operational efficiency.

By leveraging cutting-edge technologies, regulatory compliance, and a strong emphasis on customer-centric solutions, these organizations are carving out a strong presence in a market that continues to expand as new therapies and drugs are developed. The rise in biopharmaceuticals also adds impetus to the need for robust ADME (Absorption, Distribution, Metabolism, and Excretion) testing services, positioning players to effectively navigate market trends and capitalize on emerging opportunities.

Intertek has established a formidable presence in the US ADME Toxicology Testing Market, leveraging its extensive experience and expertise in the field to deliver high-quality testing services. Known for its commitment to maintaining rigorous quality standards, Intertek is widely recognized for its ability to adapt to the complex regulatory landscape, ensuring compliance with FDA and other regulatory bodies. The company's strengths lie in its comprehensive testing capabilities, which include in vitro and in vivo studies that provide critical insights into the pharmacokinetics of drug candidates.

Furthermore, Intertek's global network facilitates seamless access to a variety of specialized technologies and methodologies, ensuring that its clients benefit from the latest scientific advancements. Their strategic emphasis on client relationships and customized solutions effectively positions them to meet the diverse needs of sponsors and researchers in the rapidly evolving ADME toxicology space.

Laboratory Corporation of America has solidified its role as a key player in the US ADME Toxicology Testing Market by offering a broad range of testing services that cater specifically to the needs of pharmaceutical and biotechnology companies. With a strong focus on providing accurate and timely results, Laboratory Corporation of America's services include comprehensive toxicology testing, which is instrumental in assessing the safety and efficacy of drug candidates. The company's strengths are further demonstrated through its extensive laboratory network, allowing for streamlined operations and efficient service delivery across the United States.

Additionally, Laboratory Corporation of America is known for strategic mergers and acquisitions that bolster its capabilities and enhance its market position. By integrating advanced technologies and methodologies, the company maintains its competitive edge, ensuring that it addresses the evolving needs of clients while adhering to regulatory guidelines. Their commitment to innovation and operational excellence continues to sustain their prominence in the competitive landscape of ADME toxicology testing.

### **Key Companies**

## **US ADME Toxicology Testing Market Industry Developments**

Recent developments in the US ADME Toxicology Testing Market indicate a dynamic landscape with significant growth driven by increasing demand for drug safety and efficacy assessments. Companies such as Intertek and Laboratory Corporation of America have been enhancing their testing capabilities to meet regulatory needs and consumer safety standards. Additionally, a noteworthy acquisition occurred in June 2023 when Charles River Laboratories acquired the biopharmaceutical services segment of WuXi AppTec, expanding its portfolio and strategic offerings in the toxicology space.

Moreover, investment in innovation remains high, particularly with companies like Thermo Fisher Scientific and Agilent Technologies focusing on advanced technologies to enhance testing efficiency and accuracy.

The ongoing developments in the biopharmaceutical and biotechnology sectors continue to stimulate growth in the ADME toxicology testing market, as stakeholders emphasize the importance of comprehensive assessments in drug development. Over the past few years, notable changes have included the adoption of AI and automation within testing processes, which began to gain traction around early 2021, reflecting a broader trend of technological integration across the industry. As regulatory landscapes evolve, the emphasis on reliable toxicology testing is anticipated to rise further, influencing market dynamics significantly.

## **US ADME Toxicology Testing Market Segmentation Insights**

### **ADME Toxicology Testing Market Method Outlook**

### **ADME Toxicology Testing Market Technology Outlook**

### **ADME Toxicology Testing Market Application Outlook**

### **ADME Toxicology Testing Market End-Users Outlook**

## Market Drivers

### Emerging Regulatory Frameworks

The evolving regulatory landscape is shaping the adme toxicology-testing market. Regulatory agencies in the US are increasingly emphasizing the importance of thorough toxicology assessments in the drug approval process. New guidelines and frameworks are being established to ensure that safety evaluations are comprehensive and scientifically sound. This shift is likely to increase the demand for adme toxicology-testing services, as companies must comply with stringent regulations to bring their products to market. The emphasis on data integrity and transparency in testing results is expected to further drive the growth of the adme toxicology-testing market, as stakeholders seek to meet regulatory expectations.

### Rising Demand for Drug Development

The ADME Toxicology-Testing Market is experiencing a surge in demand driven by the increasing need for drug development. Pharmaceutical companies are under pressure to expedite the drug discovery process while ensuring safety and efficacy. In 2025, the market for drug development is projected to reach approximately $200 billion in the US, necessitating robust toxicology testing to mitigate risks associated with new compounds. This trend is likely to propel the adme toxicology-testing market as companies seek reliable testing methods to comply with regulatory requirements and to enhance their product pipelines. The emphasis on early-stage testing to identify potential toxic effects is becoming a standard practice, thereby increasing the reliance on advanced toxicology testing solutions.

### Growing Investment in Biopharmaceuticals

Investment in biopharmaceuticals is a key driver for the adme toxicology-testing market. The biopharmaceutical sector is rapidly expanding, with the US market projected to reach $400 billion by 2025. This growth is accompanied by an increasing need for comprehensive toxicology testing to evaluate the safety of biologics and biosimilars. As companies invest innovative therapies, the demand for reliable adme toxicology-testing solutions is likely to rise. The complexity of biopharmaceuticals necessitates advanced testing methodologies to assess their pharmacokinetics and potential toxic effects, thereby creating opportunities for growth within the adme toxicology-testing market.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is significantly influencing the adme toxicology-testing market. As healthcare moves towards tailored therapies, understanding individual responses to drugs becomes crucial. This trend is expected to drive the demand for sophisticated toxicology testing methods that can assess the pharmacokinetics and toxicity of drugs in diverse populations. By 2025, the personalized medicine market is anticipated to exceed $100 billion in the US, which will likely necessitate enhanced toxicology testing to ensure patient safety. The ADME Toxicology-Testing Market is poised to benefit from this focus, as it provides essential data that informs drug development and patient-specific treatment plans.

### Technological Innovations in Testing Methods

Technological advancements are revolutionizing the adme toxicology-testing market. Innovations such as high-throughput screening, in vitro testing, and computational modeling are enhancing the efficiency and accuracy of toxicology assessments. These technologies enable faster and more reliable evaluations of drug safety, which is crucial in the competitive pharmaceutical landscape. As the adme toxicology-testing market adapts to these innovations, it is likely to see increased adoption of automated systems and data analytics tools. By 2025, the integration of these technologies is expected to streamline testing processes, reduce costs, and improve the overall quality of toxicology data, thereby benefiting stakeholders across the industry.

## Future Outlook

The [ADME Toxicology Testing Market](https://www.marketresearchfuture.com/reports/adme-toxicology-testing-market-6945) is projected to grow at a 7.63% CAGR from 2025 to 2035, driven by technological advancements and regulatory demands.

**New opportunities:**

- Development of AI-driven predictive toxicology models Expansion of high-throughput screening technologies Partnerships with biotech firms for innovative testing solutions

By 2035, the market is expected to achieve substantial growth, reflecting evolving industry needs.

## Segment Insights

### By Method: Cellular Assay (Largest) vs. In Silica (Fastest-Growing)

In the US adme toxicology-testing market, the market share among the methods highlights Cellular Assay as the largest contributor, owing to its established applications in early-stage drug testing and toxicology analysis. Biochemical Assay also maintains a significant position, while In Silica represents the innovative approach gaining traction, especially in computational modeling and simulations, allowing for improved predictive outcomes. Ex-vivo methods, although relevant, hold a smaller share as they are often supplementary to other testing methods. Growth trends within this segment indicate a robust shift towards In Silica methodologies, driven by advancements in software technologies and increasing regulatory pressures to reduce animal testing. The push for more ethical testing practices is propelling Research and Development in computational assays. Meanwhile, Cellular Assay continues to evolve through integration with high-throughput screening technologies, catering effectively to the growing demand from pharmaceutical companies for faster and more reliable testing solutions.

Cellular Assay (Dominant) vs. In Silica (Emerging)

Cellular Assays dominate the testing landscape due to their ability to provide real-time biological responses and detailed insights into cellular interactions and drug absorption. This method is widely adopted across laboratories for its efficacy in screening compounds early in the drug development process. On the other hand, In Silica testing is emerging rapidly, fueled by technological advancements that make complex data modeling more feasible and accessible. Its popularity is growing as it promises to streamline the testing process by predicting outcomes before physical trials, thus reducing both time and costs associated with traditional testing methods. Together, these segments illustrate a dynamic landscape where traditional methods must adapt alongside burgeoning technologies.

### By Technology: Cell Culture (Largest) vs. High Throughput (Fastest-Growing)

In the US adme toxicology-testing market, the Cell Culture segment commands the largest share, reflecting its critical role in drug development and safety assessments. High Throughput technology is rapidly gaining traction due to its efficiency in processing multiple samples simultaneously, catering to the growing demand for faster testing methods. The OMICS Technology and Molecular Imaging segments also contribute to the market but account for smaller portions compared to the leading technologies. The growth trends in this segment are primarily driven by the increasing need for expedited testing processes and advancements in technology. High Throughput techniques are enhancing the speed and accuracy of toxicology testing, appealing to a larger user base. Meanwhile, Cell Culture continues to see sustained demand, driven by ongoing investments in biopharmaceutical developments and regenerative medicine applications. Collectively, these factors position the technology segment for ongoing growth within the market.

Technology: Cell Culture (Dominant) vs. High Throughput (Emerging)

Cell Culture remains the dominant force in the US adme toxicology-testing market, marked by its extensive applications in drug testing and development processes. This method allows for precise mimicry of in vivo environments, ensuring accurate toxicity assessments. In contrast, High Throughput technology is emerging rapidly, emphasizing efficiency and capability to conduct simultaneous analyses of numerous samples. This shift is propelled by the demand for faster results without compromising on data quality. Meanwhile, OMICS Technology and Molecular Imaging offer complementary insights but are still maturing in their adoption rates, showcasing potential but lagging in overall market share compared to the more established Cell Culture.

### By Application: Systemic Toxicity (Largest) vs. Neurotoxicity (Fastest-Growing)

The market share distribution among the application segment in the US adme toxicology-testing market is diverse, highlighting the importance of various toxicological assessments. Systemic Toxicity represents a substantial portion of the market, underscoring its significance in evaluating the safety of new compounds. In contrast, Renal and Hepatotoxicity also maintain notable shares, reflecting ongoing concerns over organ-specific toxicity. Meanwhile, Neurotoxicity is gaining traction as awareness around neurological effects increases, making way for subsectors that address this area. The growth trends in this segment are driven by heightened regulatory scrutiny and an increased focus on safety assessments in drug development. Technological advancements in testing methodologies are also propelling growth, particularly for Neurotoxicity, which is becoming a focal point for researchers. Increasing investments in research and development aim to better predict toxic effects, thus driving demand in the US adme toxicology-testing market for services that assess these critical areas.

Systemic Toxicity (Dominant) vs. Neurotoxicity (Emerging)

Systemic Toxicity remains the dominant application in the US adme toxicology-testing market, characterized by its extensive use in early-stage drug testing and safety evaluation. This category encompasses a broad array of assays designed to detect potential systemic adverse effects, making it crucial for pharmaceutical and biotech companies. On the other hand, Neurotoxicity is emerging rapidly, fueled by growing recognition of neurotoxic effects in drug safety evaluations. With advancements in neurotoxicology, such as the development of in vitro models and biomarker identification, the focus is increasingly shifting towards understanding the neurological impacts of various compounds. This trend indicates a potential shift in testing priorities as the industry adapts to new scientific findings.

### By End User: Hospitals and Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US adme toxicology-testing market, Hospitals and Clinics hold the largest market share, reflecting a significant portion of the overall demand driven by patient treatments and inpatient care requirements. Diagnostic Centers have established a strong foothold, catering to the increasing needs for specialized testing services, although their market share is smaller compared to Hospitals and Clinics. The growth trend for Diagnostic Centers is particularly notable, as they are emerging as the fastest-growing segment in the US adme toxicology-testing market. This growth is attributed to various factors, including the rising prevalence of chronic diseases, advancements in testing technologies, and the increasing investment in healthcare infrastructure supporting specialized diagnostic services. Therefore, while Hospitals and Clinics remain dominant, Diagnostic Centers are rapidly expanding in response to changing healthcare dynamics.

Hospitals and Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals and Clinics represent the dominant segment in the US adme toxicology-testing market, primarily due to their extensive utilization of toxicology tests as part of patient management and treatment protocols. These establishments are equipped with advanced facilities and a comprehensive range of services that allow for effective administration of toxicology tests, catering to various clinical needs. In contrast, Diagnostic Centers are considered an emerging segment. They are rapidly gaining traction by leveraging technology and offering specialized services that enhance accuracy and speed of testing. The focus on patient-centric care and the demand for quick test results drive the growth of Diagnostic Centers, positioning them as vital players in the evolving landscape of toxicology testing.

## Competitive Benchmarking

The ADME Toxicology-Testing Market is characterized by a dynamic competitive landscape, driven by increasing regulatory demands and the need for innovative drug development solutions. Key players such as Thermo Fisher Scientific (US), Agilent Technologies (US), and Charles River Laboratories (US) are at the forefront, leveraging their extensive portfolios and technological advancements to enhance their market positions. Thermo Fisher Scientific (US) focuses on integrating advanced analytics and automation into its testing services, which appears to streamline workflows and improve accuracy. Meanwhile, Agilent Technologies (US) emphasizes partnerships with biotech firms to expand its service offerings, indicating a strategy aimed at fostering innovation through collaboration. Charles River Laboratories (US) has adopted a strategy of regional expansion, particularly in emerging markets, which suggests a commitment to capturing new growth opportunities in diverse geographical areas.The business tactics employed by these companies include optimizing supply chains and localizing manufacturing to enhance responsiveness to market demands. The market structure is moderately fragmented, with several players competing for market share. However, the collective influence of these key players shapes a competitive environment where innovation and service quality are paramount.
In October Thermo Fisher Scientific (US) announced the launch of a new suite of automated toxicology testing solutions designed to reduce turnaround times by 30%. This strategic move is likely to enhance their competitive edge by addressing the growing demand for faster testing services, thereby attracting a broader client base. Similarly, in September 2025, Agilent Technologies (US) entered into a strategic partnership with a leading pharmaceutical company to co-develop next-generation toxicology assays. This collaboration not only strengthens Agilent's product offerings but also positions it as a key player in the evolving landscape of personalized medicine.
In August Charles River Laboratories (US) expanded its laboratory facilities in the Midwest, a decision that appears to be driven by the increasing demand for comprehensive toxicology testing services. This expansion is expected to enhance their operational capacity and improve service delivery, thereby solidifying their market position. Furthermore, in July 2025, Covance (US) launched a new digital platform aimed at integrating AI into toxicology testing processes, which may significantly enhance data analysis capabilities and improve decision-making for clients.
As of November current competitive trends in the adme toxicology-testing market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, with a greater emphasis on technological advancements and supply chain reliability rather than solely on price. This shift underscores the importance of innovation as a key driver of success in the market.

## Recent News & Developments

Recent developments in the US ADME Toxicology Testing Market indicate a dynamic landscape with significant growth driven by increasing demand for drug safety and efficacy assessments. Companies such as Intertek and Laboratory Corporation of America have been enhancing their testing capabilities to meet regulatory needs and consumer safety standards. Additionally, a noteworthy acquisition occurred in June 2023 when Charles River Laboratories acquired the biopharmaceutical services segment of WuXi AppTec, expanding its portfolio and strategic offerings in the toxicology space.

Moreover, investment in innovation remains high, particularly with companies like Thermo Fisher Scientific and Agilent Technologies focusing on advanced technologies to enhance testing efficiency and accuracy.

The ongoing developments in the biopharmaceutical and biotechnology sectors continue to stimulate growth in the ADME toxicology testing market, as stakeholders emphasize the importance of comprehensive assessments in drug development. Over the past few years, notable changes have included the adoption of AI and automation within testing processes, which began to gain traction around early 2021, reflecting a broader trend of technological integration across the industry. As regulatory landscapes evolve, the emphasis on reliable toxicology testing is anticipated to rise further, influencing market dynamics significantly.

## Report Scope

| MARKET SIZE 2024 | 1276.42(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1373.81(USD Million) |
| MARKET SIZE 2035 | 2866.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.63% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Agilent Technologies (US), PerkinElmer (US), Charles River Laboratories (US), Sierra Sciences (US), Eurofins Scientific (LU), Covance (US), Bioanalytical Systems (US), Wuxi AppTec (CN) |
| Segments Covered | Method, Technology, Application, End User |
| Key Market Opportunities | Advancements in in vitro testing methods enhance efficiency in the adme toxicology-testing market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation in the adme toxicology-testing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US adme toxicology-testing market in 2024?**
A: The market valuation was $1276.42 Million in 2024.

**Q: What is the projected market valuation for the US adme toxicology-testing market by 2035?**
A: The projected valuation for 2035 is $2866.0 Million.

**Q: What is the expected CAGR for the US adme toxicology-testing market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 7.63%.

**Q: Which companies are considered key players in the US adme toxicology-testing market?**
A: Key players include Thermo Fisher Scientific, Agilent Technologies, and Charles River Laboratories.

**Q: What are the main segments of the US adme toxicology-testing market?**
A: The main segments include Method, Technology, Application, and End User.

**Q: What was the valuation range for Cellular Assays in the Method segment in 2024?**
A: The valuation range for Cellular Assays was $200.0 Million to $450.0 Million.

**Q: How much is the High Throughput technology segment projected to be valued by 2035?**
A: The High Throughput technology segment is projected to be valued between $400.0 Million and $900.0 Million.

**Q: What applications are included in the US adme toxicology-testing market?**
A: Applications include Systemic Toxicity, Renal Toxicity, and Hepatotoxicity.

**Q: What is the projected valuation for Pathological Labs as an end user by 2035?**
A: The projected valuation for Pathological Labs is between $350.0 Million and $800.0 Million.

**Q: What does the market data suggest about the growth potential of the US adme toxicology-testing market?**
A: The data suggests a robust growth potential, with a projected increase to $2866.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-adme-toxicology-testing-market-19285*